(MLAB) Mesa Laboratories - Overview
Stock: Sterilization, Genomics, Biopharma, Calibration
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.71% |
| Yield on Cost 5y | 0.29% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 96.1% |
| Payout Ratio | 7.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 53.2% |
| Relative Tail Risk | -7.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.45 |
| Alpha | -52.79 |
| Character TTM | |
|---|---|
| Beta | 1.414 |
| Beta Downside | 1.110 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.45% |
| CAGR/Max DD | -0.28 |
Description: MLAB Mesa Laboratories December 26, 2025
Mesa Laboratories (NASDAQ: MLAB) is a diversified provider of life-sciences tools and quality-control solutions operating across four primary segments: Sterilization & Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. The company designs, manufactures, and services products that enable pharmaceutical, medical-device, dental, and research customers to verify sterilization efficacy, perform high-throughput genetic testing, conduct microfluidic protein and peptide analyses, and calibrate critical process parameters.
In FY 2023 the firm generated roughly $350 million in revenue, with the Sterilization & Disinfection Control segment contributing about 38% of sales and the Clinical Genomics segment delivering a 12% year-over-year growth rate, driven by expanding pharmacogenomics and infectious-disease testing volumes.
Key economic drivers for Mesa include the sustained growth of the global life-sciences tools market-estimated at a CAGR of 6% through 2028-and heightened regulatory scrutiny that fuels demand for validated sterilization indicators and calibration equipment. Additionally, the accelerating adoption of precision-medicine and companion-diagnostic testing underpins the upside potential for the Clinical Genomics line.
Operating margins have hovered around 12% after a modest increase in R&D spend to roughly 10% of revenue, reflecting Mesa’s focus on expanding its microfluidic and genomics platforms while maintaining a disciplined cost structure.
For analysts seeking a deeper quantitative view, the company’s recent 10-Q highlights a cash-conversion cycle of 45 days and a net-debt-to-cash ratio well below 0.5, indicating strong liquidity to fund incremental product launches.
Exploring ValueRay’s analyst dashboards can help you quickly compare Mesa’s valuation multiples against peers in the Life Sciences Tools & Services sub-industry.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 3.73m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.17 > 1.0 |
| NWC/Revenue: 20.70% < 20% (prev -18.94%; Δ 39.64% < -1%) |
| CFO/TA 0.10 > 3% & CFO 41.5m > Net Income 3.73m |
| Net Debt (74.4m) to EBITDA (44.3m): 1.68 < 3 |
| Current Ratio: 1.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.57m) vs 12m ago 2.51% < -2% |
| Gross Margin: 60.61% > 18% (prev 0.63%; Δ 5998 % > 0.5%) |
| Asset Turnover: 56.78% > 50% (prev 54.39%; Δ 2.39% > 0%) |
| Interest Coverage Ratio: 1.61 > 6 (EBITDA TTM 44.3m / Interest Expense TTM 10.6m) |
Altman Z'' 0.47
| A: 0.12 (Total Current Assets 105.6m - Total Current Liabilities 54.4m) / Total Assets 434.8m |
| B: -0.42 (Retained Earnings -180.7m / Total Assets 434.8m) |
| C: 0.04 (EBIT TTM 17.1m / Avg Total Assets 436.0m) |
| D: 0.75 (Book Value of Equity 186.7m / Total Liabilities 248.2m) |
| Altman-Z'' Score: 0.47 = B |
Beneish M -3.05
| DSRI: 1.00 (Receivables 40.2m/38.6m, Revenue 247.5m/237.7m) |
| GMI: 1.03 (GM 60.61% / 62.68%) |
| AQI: 1.02 (AQ_t 0.68 / AQ_t-1 0.67) |
| SGI: 1.04 (Revenue 247.5m / 237.7m) |
| TATA: -0.09 (NI 3.73m - CFO 41.5m) / TA 434.8m) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of MLAB shares?
Over the past week, the price has changed by +15.86%, over one month by +10.67%, over three months by +14.21% and over the past year by -39.30%.
Is MLAB a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the MLAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.5 | 12% |
| Analysts Target Price | 104.5 | 12% |
| ValueRay Target Price | 83.9 | -10.1% |
MLAB Fundamental Data Overview February 08, 2026
P/E Forward = 35.2113
P/S = 2.0817
P/B = 2.7152
Revenue TTM = 247.5m USD
EBIT TTM = 17.1m USD
EBITDA TTM = 44.3m USD
Long Term Debt = 161.0m USD (from longTermDebt, last quarter)
Short Term Debt = 5.16m USD (from shortTermDebt, last quarter)
Debt = 103.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 74.4m USD (from netDebt column, last quarter)
Enterprise Value = 589.7m USD (515.3m + Debt 103.4m - CCE 29.0m)
Interest Coverage Ratio = 1.61 (Ebit TTM 17.1m / Interest Expense TTM 10.6m)
EV/FCF = 15.65x (Enterprise Value 589.7m / FCF TTM 37.7m)
FCF Yield = 6.39% (FCF TTM 37.7m / Enterprise Value 589.7m)
FCF Margin = 15.23% (FCF TTM 37.7m / Revenue TTM 247.5m)
Net Margin = 1.51% (Net Income TTM 3.73m / Revenue TTM 247.5m)
Gross Margin = 60.61% ((Revenue TTM 247.5m - Cost of Revenue TTM 97.5m) / Revenue TTM)
Gross Margin QoQ = 64.18% (prev 61.46%)
Tobins Q-Ratio = 1.36 (Enterprise Value 589.7m / Total Assets 434.8m)
Interest Expense / Debt = 2.94% (Interest Expense 3.04m / Debt 103.4m)
Taxrate = 21.02% (966.0k / 4.60m)
NOPAT = 13.5m (EBIT 17.1m * (1 - 21.02%))
Current Ratio = 1.94 (Total Current Assets 105.6m / Total Current Liabilities 54.4m)
Debt / Equity = 0.55 (Debt 103.4m / totalStockholderEquity, last quarter 186.7m)
Debt / EBITDA = 1.68 (Net Debt 74.4m / EBITDA 44.3m)
Debt / FCF = 1.97 (Net Debt 74.4m / FCF TTM 37.7m)
Total Stockholder Equity = 174.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.86% (Net Income 3.73m / Total Assets 434.8m)
RoE = 2.14% (Net Income TTM 3.73m / Total Stockholder Equity 174.4m)
RoCE = 5.08% (EBIT 17.1m / Capital Employed (Equity 174.4m + L.T.Debt 161.0m))
RoIC = 3.85% (NOPAT 13.5m / Invested Capital 349.4m)
WACC = 9.65% (E(515.3m)/V(618.7m) * Re(11.12%) + D(103.4m)/V(618.7m) * Rd(2.94%) * (1-Tc(0.21)))
Discount Rate = 11.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 73.06% ; FCFF base≈39.8m ; Y1≈41.6m ; Y5≈48.2m
Fair Price DCF = 101.5 (EV 635.1m - Net Debt 74.4m = Equity 560.6m / Shares 5.52m; r=9.65% [WACC]; 5y FCF grow 4.93% → 2.90% )
EPS Correlation: 81.24 | EPS CAGR: 171.3% | SUE: -0.09 | # QB: 0
Revenue Correlation: 66.77 | Revenue CAGR: 2.73% | SUE: 0.92 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.06 | Chg30d=-0.490 | Revisions Net=-1 | Analysts=1
EPS next Year (2027-03-31): EPS=5.39 | Chg30d=-0.670 | Revisions Net=-1 | Growth EPS=-26.7% | Growth Revenue=+5.0%